RxDoctor Payments Data

Sin Kei Yeung, MD

Internal Medicine · Drexel Hill, PANPI 1669704607

Payments from drug & device makers

$9,854in general payments, 2019–2025

Across 607 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$922
  • GSK$816
  • Novo Nordisk$704
  • Boehringer Ingelheim$638
  • Astellas Pharma US Inc$630
  • plus $5K from 36 others

What the payments were for

  • Speaking & faculty fees$761%
  • Food & beverage$9,74499%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,854 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,220
Medicare patients
217
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban303$100,632
OzempicSemaglutide100$100,474
OtezlaApremilast11$71,155
JanuviaSitagliptin Phosphate158$66,528
JardianceEmpagliflozin81$52,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$51,808
NuplazidPimavanserin Tartrate18$46,473
LinzessLinaclotide47$29,496
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$26,152
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$24,877
MyrbetriqMirabegron99$22,971
TrulicityDulaglutide17$20,297
XareltoRivaroxaban20$19,898
Breo ElliptaFluticasone/Vilanterol28$16,084
Budesonide72$13,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy$816$104,337176 claims
PfizerEliquis$491$100,632303 claims
Novo NordiskOzempic$704$100,474100 claims
MerckJanuvia, Janumet Xr, Janumet$478$88,262190 claims
AmgenOtezla$414$71,15511 claims
Boehringer IngelheimJardiance, Stiolto Respimat$638$64,845100 claims
Acadia Pharmaceuticals IncNuplazid$15$46,47318 claims
AbbVieLinzess, Creon, Restasis$1,618$44,92771 claims
Lilly USA, LLCTrulicity, Mounjaro$922$33,18328 claims
AstraZenecaBreztri Aerosphere$504$26,15229 claims
Astellas Pharma US IncMyrbetriq$630$22,97199 claims
Johnson & JohnsonXarelto$179$19,89820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Drexel Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →